Need Help?
Email Course Coordinator

Why Use Adis R&D Insight?

Each file on Dialog has its advantages. Note the major benefits of this file below.

• Content of particular interest to those working in pharmaceutical R&D, licensing and marketing and researchers in healthcare institutions.
• Contains adverse events data.
• Includes the therapeutic classification scheme developed by the European Pharmaceutical Market Research Association (EPhMRA) and also contains World Health Organization (WHO) classification.
• Provides extensive pharmacological and pharmacokinetic information
• One of the best sources for nomenclature—drug names, synonyms.
• Consistently classifies drugs by indication with coordinated indexing of indications with stage of development and target markets
• Provides Adis therapeutic value rating related to specific indications.
• Contains commercial summary and forecast by Lehman Brothers.

Go to the next page.